Fulcrum therapeutics to present new data from the open label extension of phase 2 redux4 study at the world muscle society (wms) congress in halifax, canada

- 96-week findings support losmapimod as a disease-modifying therapy for fshd
FULC Ratings Summary
FULC Quant Ranking